id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2026-N-0131-0001,FDA,FDA-2026-N-0131,FDA Rare Disease Innovation Hub Future Programming; Request for Comments,Notice,Request for Comments,2026-01-30,2026,1,2026-01-30,2027-01-01,2026-03-22 09:00:09,2026-01903,1,0,09000064b91893ee
FDA-2016-D-1280-0005,FDA,FDA-2016-D-1280,"Electronic Submission of Postmarketing Individual Case Safety Reports to the Food and Drug Administration Adverse Event Monitoring System Using International
Council of Harmonisation E2B(R3) Data Standards; Regional Data Elements and Implementation Schedule",Notice,Announcement,2026-04-06,2026,4,2026-04-06,2026-10-02,2026-04-07 09:00:25,2026-06660,1,0,09000064b9253dbc
FDA-2025-E-2426-0006,FDA,FDA-2025-E-2426,Determination of Regulatory Review Period for Purposes of Patent Extension; BLUJEPA,Notice,Determinations,2026-02-13,2026,2,2026-02-13,2026-08-13,2026-02-13 20:03:13,2026-02901,1,0,09000064b91aa6fb
FDA-2025-E-0152-0006,FDA,FDA-2025-E-0152,Determination of Regulatory Review Period for Purposes of Patent Extension; COBENFY,Notice,Determinations,2026-02-06,2026,2,2026-02-06,2026-08-06,2026-02-06 20:05:43,2026-02388,1,0,09000064b919467e
FDA-2025-E-0153-0006,FDA,FDA-2025-E-0153,Determination of Regulatory Review Period for Purposes of Patent Extension; COBENFY,Notice,Determinations,2026-02-06,2026,2,2026-02-06,2026-08-06,2026-02-06 20:06:34,2026-02388,1,0,09000064b919467f
FDA-2024-E-3539-0006,FDA,FDA-2024-E-3539,Determination of Regulatory Review Period for Purposes of Patent Extension; BEQVEZ,Notice,Determinations,2026-02-06,2026,2,2026-02-06,2026-08-06,2026-02-14 13:19:52,2026-02387,1,0,09000064b9195b4d
FDA-2025-E-0154-0006,FDA,FDA-2025-E-0154,Determination of Regulatory Review Period for Purposes of Patent Extension; COBENFY,Notice,Determinations,2026-02-06,2026,2,2026-02-06,2026-08-06,2026-02-06 20:07:01,2026-02388,1,0,09000064b9195c17
FDA-2026-N-3273-0001,FDA,FDA-2026-N-3273,"Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments; Public Meeting; Request for Comments",Notice,Request for Comments,2026-04-15,2026,4,2026-04-15,2026-07-24,2026-04-15 17:05:22,2026-07248,1,0,09000064b9282224
FDA-2023-N-0119-0020,FDA,FDA-2023-N-0119,"Fiscal Year 2026 Generic Drug Science and Research Initiatives Workshop; Public Workshop; Request for
Comments",Notice,Request for Comments,2026-02-27,2026,2,2026-02-27,2026-07-11,2026-04-14 09:00:18,2026-03961,1,0,09000064b91e326c
FDA-2026-N-2366-0001,FDA,FDA-2026-N-2366,Commissioner’s National Priority Voucher (CNPV) Pilot Program; Public Hearing; Request for Comments,Notice,Request for Comments,2026-03-23,2026,3,2026-03-23,2026-06-30,2026-04-12 09:00:14,2026-05573,1,0,09000064b922c21a
FDA-2026-N-2742-0001,FDA,FDA-2026-N-2742,Agency Information Collection Activities; Proposed Collection; Comment Request; Color Additive Certification,Notice,60 Day Proposed Information Collection,2026-04-10,2026,4,2026-04-10,2026-06-10,2026-04-10 18:01:37,2026-06936,1,0,09000064b926825a
FDA-2026-N-2743-0001,FDA,FDA-2026-N-2743,"Agency Information Collection Activities; Proposed Collection; Comment Request; Submission of Petitions: Food Additive, Color Additive (Including Labeling), Submission of Information to a Master File in Support of Petitions; and Electronic Submission Using Food and Drug Administration Form 3503",Notice,60 Day Proposed Information Collection,2026-04-10,2026,4,2026-04-10,2026-06-10,2026-04-10 18:22:24,2026-06935,1,0,09000064b926821b
FDA-2026-N-2915-0001,FDA,FDA-2026-N-2915,Agency Information Collection Activities; Proposed Collection; Comment Request; Premarket Approval of Medical Devices,Notice,60 Day Proposed Information Collection,2026-04-10,2026,4,2026-04-10,2026-06-10,2026-04-10 17:47:50,2026-06906,1,0,09000064b9268328
FDA-2026-N-2431-0001,FDA,FDA-2026-N-2431,Agency Information Collection Activities; Proposed Collection; Comment Request; Administrative Practices and Procedures; Formal Hearings,Notice,60 Day Proposed Information Collection,2026-04-07,2026,4,2026-04-07,2026-06-09,2026-04-14 19:40:33,2026-06719,1,0,09000064b9255485
FDA-2025-E-0863-0006,FDA,FDA-2025-E-0863,Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY,Notice,Determinations,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 17:37:03,2026-06478,1,0,09000064b924cccb
FDA-2025-E-0845-0006,FDA,FDA-2025-E-0845,Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY,Notice,Determinations,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 17:34:01,2026-06478,1,0,09000064b924dac3
FDA-2025-E-0866-0006,FDA,FDA-2025-E-0866,Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY,Notice,Determinations,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 17:42:13,2026-06478,1,0,09000064b924ccce
FDA-2025-E-0372-0005,FDA,FDA-2025-E-0372,Determination of Regulatory Review Period for Purposes of Patent Extension; ZIIHERA,Notice,Determinations,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 17:52:42,2026-06476,1,0,09000064b924da88
FDA-2025-E-3074-0006,FDA,FDA-2025-E-3074,Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS,Notice,Determinations,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 17:57:30,2026-06480,1,0,09000064b924c470
FDA-2025-E-0871-0006,FDA,FDA-2025-E-0871,Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY,Notice,Determinations,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 17:49:10,2026-06478,1,0,09000064b924c46e
FDA-2025-E-3073-0006,FDA,FDA-2025-E-3073,Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS,Notice,Determinations,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 17:55:54,2026-06480,1,0,09000064b924da86
FDA-2025-E-3626-0006,FDA,FDA-2025-E-3626,Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA,Notice,Determinations,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 17:59:57,2026-06479,1,0,09000064b924d98d
FDA-2025-E-0870-0006,FDA,FDA-2025-E-0870,Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY,Notice,Determinations,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 17:48:07,2026-06478,1,0,09000064b924c46d
FDA-2026-N-2740-0001,FDA,FDA-2026-N-2740,Agency Information Collection Activities; Proposed Collection; Comment Request; Customer/Partner Customer Service Satisfaction Surveys,Notice,60 Day Proposed Information Collection,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 17:29:44,2026-06482,1,0,09000064b924dac4
FDA-2025-E-0868-0006,FDA,FDA-2025-E-0868,Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY,Notice,Determinations,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 17:44:23,2026-06478,1,0,09000064b924c0e1
FDA-2025-E-0865-0006,FDA,FDA-2025-E-0865,Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY,Notice,Determinations,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 17:39:45,2026-06478,1,0,09000064b924cccd
FDA-2025-E-1672-0007,FDA,FDA-2025-E-1672,Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO,Notice,Determinations,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 18:06:28,2026-06477,1,0,09000064b924d940
FDA-2014-E-2328-0006,FDA,FDA-2014-E-2328,Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER,Notice,Determinations,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 18:09:13,2026-06483,1,0,09000064b924d4f5
FDA-2025-E-0864-0006,FDA,FDA-2025-E-0864,Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY,Notice,Determinations,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 17:38:27,2026-06478,1,0,09000064b924cccc
FDA-2025-E-0872-0006,FDA,FDA-2025-E-0872,Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY,Notice,Determinations,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 17:50:02,2026-06478,1,0,09000064b924c46f
FDA-2025-E-0867-0006,FDA,FDA-2025-E-0867,Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY,Notice,Determinations,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 17:43:31,2026-06478,1,0,09000064b924c0e0
FDA-2025-E-0158-0006,FDA,FDA-2025-E-0158,Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI,Notice,Determinations,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 18:04:00,2026-06481,1,0,09000064b924d942
FDA-2025-E-0869-0006,FDA,FDA-2025-E-0869,Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY,Notice,Determinations,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 17:45:32,2026-06478,1,0,09000064b924ba07
FDA-2026-N-0809-0001,FDA,FDA-2026-N-0809,Recommendations on Scale-Up and Postapproval Changes Guidances for Industry; Request for Comments,Notice,Request for Comments,2026-03-03,2026,3,2026-03-03,2026-06-02,2026-04-13 09:00:28,2026-04196,1,0,09000064b91ed501
FDA-2026-N-2476-0001,FDA,FDA-2026-N-2476,"Advancing the Use of Digital Health Technologies in Clinical Investigations for Drugs and Biological Products;
Request for Information and Comments",Notice,Request for Comments,2026-03-31,2026,3,2026-03-31,2026-06-02,2026-04-10 09:00:28,2026-06184,1,0,09000064b92439d6
FDA-2024-E-5140-0006,FDA,FDA-2024-E-5140,Determination of Regulatory Review Period for Purposes of Patent Extension; ENVISION MAMMOGRAPHY PLATFORM,Notice,Determinations,2025-11-24,2025,11,2025-11-24,2026-05-27,2026-01-24 13:16:48,2025-20667,1,0,09000064b908e3f0
FDA-2024-E-5139-0006,FDA,FDA-2024-E-5139,Determination of Regulatory Review Period for Purposes of Patent Extension; ENVISION MAMMOGRAPHY PLATFORM,Notice,Determinations,2025-11-24,2025,11,2025-11-24,2026-05-27,2026-01-24 13:16:48,2025-20667,1,0,09000064b908e3ef
FDA-2024-E-5141-0006,FDA,FDA-2024-E-5141,Determination of Regulatory Review Period for Purposes of Patent Extension; ENVISION MAMMOGRAPHY PLATFORM,Notice,Determinations,2025-11-24,2025,11,2025-11-24,2026-05-27,2026-01-24 13:16:50,2025-20667,1,0,09000064b9092f99
FDA-2024-E-5681-0006,FDA,FDA-2024-E-5681,"Determination of Regulatory Review Period for Purposes of Patent Extension; ALTIUS DIRECT ELECTRICAL NERVE STIMULATION
SYSTEM",Notice,Determinations,2025-11-24,2025,11,2025-11-24,2026-05-27,2025-11-24 19:32:14,2025-20668,1,0,09000064b9093521
FDA-2026-N-2365-0001,FDA,FDA-2026-N-2365,Agency Information Collection Activities; Proposed Collection; Comment Request; Reporting Associated With Animal Drug and Animal Generic Drug User Fees,Notice,60 Day Proposed Information Collection,2026-03-23,2026,3,2026-03-23,2026-05-23,2026-03-23 17:37:47,2026-05620,1,0,09000064b922c25e
FDA-2026-N-2364-0001,FDA,FDA-2026-N-2364,"Agency Information Collection Activities; Proposed Collection; Comment Request; Food and Drug
Administration Advisory Committees",Notice,60 Day Proposed Information Collection,2026-03-23,2026,3,2026-03-23,2026-05-23,2026-03-25 09:00:29,2026-05623,1,0,09000064b922c187
FDA-2026-N-1849-0001,FDA,FDA-2026-N-1849,Agency Information Collection Activities; Proposed Collection; Comment Request; Premarket Notifications Submission,Notice,60 Day Proposed Information Collection,2026-03-19,2026,3,2026-03-19,2026-05-19,2026-03-19 17:24:48,2026-05329,1,0,09000064b9224334
FDA-2026-N-2279-0001,FDA,FDA-2026-N-2279,Preparation for International Cooperation on Cosmetics Regulation Twentieth Annual Meeting (ICCR–20); Request for Comments,Notice,Request for Comments,2026-03-18,2026,3,2026-03-18,2026-05-19,2026-04-03 09:00:22,2026-05280,1,0,09000064b922165c
FDA-2026-N-1736-0001,FDA,FDA-2026-N-1736,Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational New Drug Application Requirements,Notice,60 Day Proposed Information Collection,2026-03-13,2026,3,2026-03-13,2026-05-13,2026-03-13 17:05:05,2026-04938,1,0,09000064b92145ad
FDA-2025-N-4731-0052,FDA,FDA-2025-N-4731,Increasing Access to Nonprescription Drugs; Public Meeting; Request for Comments,Notice,Request for Comments,2026-04-15,2026,4,2026-04-15,2026-05-09,2026-04-15 17:08:45,2026-07335,1,0,09000064b9282192
FDA-2025-E-0493-0006,FDA,FDA-2025-E-0493,Determination of Regulatory Review Period for Purposes of Patent Extension; ENSACOVE,Notice,Determinations,2026-03-06,2026,3,2026-03-06,2026-05-06,2026-03-06 19:06:30,2026-04491,1,0,09000064b91f8458
FDA-2026-N-2741-0001,FDA,FDA-2026-N-2741,Consideration of Acceptable Market Name Change for Certain Rockfish (Sebastes spp.); Request for Information,Notice,Requests for Information (RFI),2026-04-01,2026,4,2026-04-01,2026-05-02,2026-04-14 19:40:35,2026-06294,1,0,09000064b924995a
FDA-2026-N-1867-0001,FDA,FDA-2026-N-1867,"Oncologic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments—New Drug Application 220359, for Camizestrant Tablets; Supplemental New Drug Application (sNDA) 218197/S–004, for Truqap (Capivasertib) Tablets",Notice,Request for Comments,2026-03-09,2026,3,2026-03-09,2026-04-30,2026-04-16 09:00:12,2026-04497,1,0,09000064b9200842
FDA-2026-N-0686-0001,FDA,FDA-2026-N-0686,"Agency Information Collection Activities; Proposed Collection; Comment Request; Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements",Notice,60 Day Proposed Information Collection,2026-02-24,2026,2,2026-02-24,2026-04-28,2026-02-24 19:45:30,2026-03589,1,0,09000064b91d5809
FDA-2024-E-3572-0007,FDA,FDA-2024-E-3572,Determination of Regulatory Review Period for Purposes of Patent Extension; TEVIMBRA,Notice,Determinations,2026-02-26,2026,2,2026-02-26,2026-04-28,2026-02-26 20:52:55,2026-03851,1,0,09000064b91deb48
FDA-2025-E-0161-0006,FDA,FDA-2025-E-0161,Determination of Regulatory Review Period for Purposes of Patent Extension; ORLYNVAH,Notice,Determinations,2026-02-26,2026,2,2026-02-26,2026-04-28,2026-02-26 20:55:38,2026-03848,1,0,09000064b91deb09
FDA-2024-E-3565-0006,FDA,FDA-2024-E-3565,Determination of Regulatory Review Period for Purposes of Patent Extension; LIMFLOW SYSTEM,Notice,Determinations,2026-02-26,2026,2,2026-02-26,2026-04-28,2026-02-26 20:38:14,2026-03855,1,0,09000064b91e03ee
FDA-2024-E-3555-0007,FDA,FDA-2024-E-3555,Determination of Regulatory Review Period for Purposes of Patent Extension; LIMFLOW SYSTEM,Notice,Determinations,2026-02-26,2026,2,2026-02-26,2026-04-28,2026-02-26 20:35:08,2026-03855,1,0,09000064b91dec48
FDA-2025-E-1226-0007,FDA,FDA-2025-E-1226,Determination of Regulatory Review Period for Purposes of Patent Extension; AEROPACE,Notice,Determinations,2026-02-26,2026,2,2026-02-26,2026-04-28,2026-02-26 20:32:36,2026-03849,1,0,09000064b91dec81
FDA-2025-E-1229-0006,FDA,FDA-2025-E-1229,Determination of Regulatory Review Period for Purposes of Patent Extension; MERIT MEDICAL WRAPSODY,Notice,Determinations,2026-02-26,2026,2,2026-02-26,2026-04-28,2026-02-26 20:43:12,2026-03853,1,0,09000064b91e03f1
FDA-2025-E-0371-0006,FDA,FDA-2025-E-0371,Determination of Regulatory Review Period for Purposes of Patent Extension; REVUFORJ,Notice,Determinations,2026-02-26,2026,2,2026-02-26,2026-04-28,2026-02-26 20:46:51,2026-03847,1,0,09000064b91dec08
FDA-2024-E-3564-0006,FDA,FDA-2024-E-3564,Determination of Regulatory Review Period for Purposes of Patent Extension; LIMFLOW SYSTEM,Notice,Determinations,2026-02-26,2026,2,2026-02-26,2026-04-28,2026-02-26 20:36:56,2026-03855,1,0,09000064b91e03ed
FDA-2025-E-0500-0006,FDA,FDA-2025-E-0500,Determination of Regulatory Review Period for Purposes of Patent Extension; TRYNGOLZA,Notice,Determinations,2026-02-26,2026,2,2026-02-26,2026-04-28,2026-02-26 20:57:25,2026-03850,1,0,09000064b91deac5
FDA-2025-E-1228-0006,FDA,FDA-2025-E-1228,Determination of Regulatory Review Period for Purposes of Patent Extension; MERIT MEDICAL WRAPSODY,Notice,Determinations,2026-02-26,2026,2,2026-02-26,2026-04-28,2026-02-27 10:00:26,2026-03853,1,0,09000064b91dec45
FDA-2026-N-0027-0001,FDA,FDA-2026-N-0027,"Agency Information Collection Activities; Proposed Collection; Comment Request; Biological Products: Reporting of Biological Product Deviations and Human Cells, Tissues, and Cellular and Tissue-Based Product Deviations in Manufacturing",Notice,60 Day Proposed Information Collection,2026-02-25,2026,2,2026-02-25,2026-04-28,2026-02-25 19:16:33,2026-03773,1,0,09000064b91da53a
FDA-2026-N-0496-0001,FDA,FDA-2026-N-0496,Agency Information Collection Activities; Proposed Collection; Comment Request; Current Good Manufacturing Practice Regulations for Medicated Feeds,Notice,60 Day Proposed Information Collection,2026-02-25,2026,2,2026-02-25,2026-04-28,2026-04-03 09:00:19,2026-03772,1,0,09000064b91da591
FDA-2023-P-3942-1120,FDA,FDA-2023-P-3942,Labeling and Preventing Cross-Contact of Gluten for Packaged Foods; Request for Information,Notice,Requests for Information (RFI),2026-01-22,2026,1,2026-01-22,2026-04-23,2026-04-16 09:00:08,2026-01121,1,0,09000064b91781b1
FDA-2026-N-0746-0001,FDA,FDA-2026-N-0746,"Agency Information Collection Activities; Proposed Collection; Comment Request; Current Good Manufacturing Practice (CGMP): Manufacturing, Processing, Packing, and Holding of Drugs; GMP for
Finished Pharmaceuticals (Including Active Pharmaceutical Ingredients) and the Advanced Manufacturing
Technologies Designation Program",Notice,60 Day Proposed Information Collection,2026-02-20,2026,2,2026-02-20,2026-04-22,2026-03-14 09:00:11,2026-03326,1,0,09000064b91c75af
FDA-2026-N-1305-0001,FDA,FDA-2026-N-1305,Agency Information Collection Activities; Proposed Collection; Comment Request; New Animal Drugs for Minor Use and Minor Species,Notice,60 Day Proposed Information Collection,2026-02-20,2026,2,2026-02-20,2026-04-22,2026-04-06 09:00:14,2026-03353,1,0,09000064b91c750d
FDA-2026-N-0499-0001,FDA,FDA-2026-N-0499,Agency Information Collection Activities; Proposed Collection; Comment Request; Hazard Analysis and Critical Control Point Procedures for the Safe and Sanitary Processing and Importing of Juice,Notice,60 Day Proposed Information Collection,2026-02-20,2026,2,2026-02-20,2026-04-22,2026-02-20 20:23:05,2026-03332,1,0,09000064b91c75b1
FDA-2026-N-1303-0001,FDA,FDA-2026-N-1303,Agency Information Collection Activities; Proposed Collection; Comment Request; Adverse Events Associated With New Animal Drugs,Notice,60 Day Proposed Information Collection,2026-02-20,2026,2,2026-02-20,2026-04-22,2026-02-20 20:55:00,2026-03352,1,0,09000064b91c3035
FDA-2026-N-0684-0001,FDA,FDA-2026-N-0684,Agency Information Collection Activities; Proposed Collection; Comment Request; Approved Organizations for Wholesale Drug Distributors and Third-Party Logistics Providers,Notice,60 Day Proposed Information Collection,2026-02-20,2026,2,2026-02-20,2026-04-22,2026-02-20 20:51:55,2026-03333,1,0,09000064b91c307f
FDA-2026-N-0497-0001,FDA,FDA-2026-N-0497,"Agency Information Collection Activities; Proposed Collection; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions",Notice,60 Day Proposed Information Collection,2026-02-18,2026,2,2026-02-18,2026-04-21,2026-02-18 19:12:13,2026-03094,1,0,09000064b91b8f13
FDA-2026-N-0498-0001,FDA,FDA-2026-N-0498,Agency Information Collection Activities; Proposed Collection; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products,Notice,60 Day Proposed Information Collection,2026-02-19,2026,2,2026-02-19,2026-04-21,2026-02-19 20:20:32,2026-03311,1,0,09000064b91bd409
FDA-2025-E-0862-0006,FDA,FDA-2025-E-0862,Determination of Regulatory Review Period for Purposes of Patent Extension; SYMVESS,Notice,Determinations,2026-02-19,2026,2,2026-02-19,2026-04-21,2026-02-19 20:54:45,2026-03312,1,0,09000064b91bd33f